कंपनी का अवलोकन
Bio Green Med Solution, Inc. (BGMS) operates within the healthcare sector, specifically functioning in the biotechnology industry, where it engages in the distribution, trading, and installation of protective and fire safety materials, equipment, and systems, alongside research and development efforts for pharmaceuticals. The company's market capitalization stands at $5.57M, while its trailing twelve-month revenue totals $747,000, indicating a small-cap enterprise with limited revenue generation relative to its valuation metrics. Although the specific employee count is not disclosed in the available data, the company's operational scope suggests a lean structure focused on niche safety solutions and drug development. This combination of a low market cap and modest revenue implies that BGMS occupies a marginal position in the broader healthcare market, relying heavily on specific project-based income streams rather than mass-market scalability typical of larger pharmaceutical entities.
वित्तीय स्वास्थ्य
The company's financial performance over the trailing twelve months shows a revenue of $747,000 paired with a net income of -$14,092,000, revealing a severe cost structure where expenses significantly exceed all income sources. The EBITDA for the same period is -$8,422,000, further confirming that core operational activities are currently generating negative cash flows before interest and taxes. Free cash flow stands at -$10,077,875, which indicates that the company is consuming cash reserves to fund operations or development without generating sufficient internal liquidity to sustain itself without external financing. Gross margin is recorded at -90.1%, operating margin at -162.5%, and profit margin at 0.0%, collectively signaling that the business model is currently unable to cover its direct costs of goods sold or general operating expenses from its top-line sales. On the balance sheet, the company holds $3.50M in cash against a negligible debt load of $2,000, resulting in a debt-to-equity ratio of 0.03, which suggests a highly conservative capital structure devoid of significant leverage risk. The current ratio of 4.70 demonstrates strong short-term liquidity, as current assets are nearly five times greater than current liabilities, providing a substantial buffer for meeting immediate obligations. Return on Equity is -128.4% and return on assets is -85.8%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently, likely due to substantial R&D expenditures or operational losses typical in early-stage biotechnology ventures.
मूल्यांकन आकलन
Trailing P/E and forward P/E ratios are both listed as N/A due to the company's lack of positive earnings, which implies that traditional valuation models based on earnings multiples are currently inapplicable for assessing BGMS. The price-to-book ratio is 0.80, suggesting that the market values the company's equity at 80% of its book value, indicating no premium over net assets and potentially reflecting market skepticism regarding future profitability. The price-to-sales ratio is 7.46, while the EV/EBITDA stands at -0.25, which suggests that investors are pricing the stock based on sales multiples rather than earnings power, a common practice for unprofitable growth companies or those with negative EBITDA. The 52-week high is $100.80 and the 52-week low is $0.73, highlighting extreme price volatility where the stock could theoretically trade anywhere within this range, though the current price sits significantly below the high mark relative to the low. The beta value is -0.53, a negative coefficient that indicates the stock's price movements are inversely correlated to the broader market, meaning the stock tends to rise when the market falls and vice versa, offering a unique risk profile distinct from standard equity investments.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of growth rates between top-line expansion and bottom-line profitability, yet the persistent negative net income suggests that earnings are not growing alongside revenue due to structural losses. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash and retained earnings are reinvested into the business operations or research initiatives rather than distributed to shareholders. This reinvestment strategy is characteristic of biotechnology firms attempting to develop new pharmaceutical products or secure regulatory approvals before achieving commercial viability. The overall growth and income profile for Bio Green Med Solution, Inc. is defined by significant financial losses and a lack of dividend income, positioning the company as a speculative asset dependent on future breakthroughs or operational turnaround rather than current cash flow generation or shareholder returns.